Fundraising Fox

Purespring

4 known investors

purespringtx.com ↗

Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells. Its pipeline targets renal indications including Alport Syndrome (PS-003) and IgA nephropathy (PS-002).

BiotechHealthtechMedical Devices

Investors · 4

Sofinnova PartnersParis · $540K – $27M
British Patient CapitalreportedLondon
ForbionreportedNaarden
Gilde HealthcarereportedUtrecht · $1.1M – $55M

In the news

News - Purespring Therapeuticspurespringtx.com · Oct 2025Syncona's Purespring raises £80m in new financing - Sharecast.comsharecast.com · Oct 2024Purespring Therapeutics raises £80M to develop gene therapies aimed at kidney diseases — TFNtechfundingnews.com · Oct 2024Purespring Therapeutics Raises $105M in Series B Financingfinsmes.com · Oct 2024Purespring Therapeutics closed US$105,000,000 in a sensational growth funding round. | Startupmagstartupmag.co.uk · Oct 2024Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases - Purespring Therapeuticspurespringtx.com · Oct 2024

Frequently asked questions

What does Purespring do?
Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells. Its pipeline targets renal indications including Alport Syndrome (PS-003) and IgA nephropathy (PS-002).
Who are Purespring's investors?
Purespring's investors include Sofinnova Partners, British Patient Capital, Forbion, Gilde Healthcare.